Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Counts 32 Billion Reasons To Reject Mylan Offers

This article was originally published in The Tan Sheet

Executive Summary

In addition to announcing it to turned down Mylan’s offer of $205 per share or roughly $28.9 billion, Perrigo reports a 41% increase in adjusted net income to a company-record $248.5 million in its latest quarter. The firm plans to launch a generic of Sanofi’s Nasacort 24 HR in time for the 2015 allergy season.

You may also be interested in...



Pfizer Notches “Milestone” In OTC Switch Plan

Nexium 24HR’s is “the first significant milestone” Pfizer’s Rx-to-OTC strategy, says Albert Bourla, head of the division that includes consumer products. The next milestone could be a new drug application for an OTC version of Lipitor.

Merck’s Oxytrol Could Be OTC Trailblazer For Chronic Conditions

Merck’s Oxytrol for Women has the opportunity to “create the market” for OTC overactive bladder drugs, as well as encourage other switches for chronic, progressive conditions, marketing consultant Joe McGovern says. The transdermal patch product is slated to launch in September.

NPA Alleges US FDA Bends Time As Well As Rules To Stop NAC’s Use As Dietary Ingredient

Trade group offers timeline for shift in FDA thinking about the amino acid commonly used in supplements in complaint seeking to block agency from preventing sales of NAC-containing supplements. Complaint also attests that, unlike its current stance, FDA in 1993 acknowledged NAC is lawful for use as a dietary ingredient.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS107627

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel